LUMIFY® is Canada's First and Only Over-the-Counter Eye Drop with Low-Dose Brimonidine for the Relief of Eye Redness

VAUGHAN, ON , May 24, 2022 /PRNewswire/ -- Bausch + Lomb Corporation (NYSE/TSX: BLCO) ("Bausch + Lomb"), a leading global eye health company dedicated to helping people see better to live better, today announced that Health Canada has approved LUMIFY® (brimonidine tartrate ophthalmic solution 0.025% w/v), the first and only over-the-counter (OTC) eye drop developed with low-dose brimonidine tartrate to relieve redness of the eye due to minor eye irritations for adults.1

"With Health Canada's approval of LUMIFY®, we are excited to be able to now offer Canadians a new option to help relieve their red, irritated eyes," said Joe Gordon , president, Global Consumer, Surgical and Vision Care. "Bausch + Lomb is dedicated to meeting the needs of eye care professionals and their patients, and we're proud to bring LUMIFY® forward as an example of our continued commitment to developing innovative eye health products."

Eye redness occurs as a result of minor eye irritations such as environmental allergies, dryness and fatigue.1 LUMIFY® works by selectively targeting redness and thereby reducing the potential for side effects such as rebound redness and tachyphylaxis.1 In clinical trials, LUMIFY® eye drops demonstrated significant reduction in ocular redness seen as early as one minute and persisted up to eight hours.1 An in-home-use-study with over 300 participants also resulted in a 95% satisfaction rating for the product.2

"Ocular redness is often one of the first things people notice when making eye contact. It can affect daily life and have a negative social impact, especially for important occasions such as critical meetings or events," said Riyad Khamis , O.D., FAAO, FCOVD, London, Ontario . "I look forward to offering my patients LUMIFY® so they can quickly reduce their eye redness due to minor eye irritations while reducing concerns of rebound hyperemia, which can lead to corneal issues."

LUMIFY® is expected to be available at all major pharmacy retailers in Canada by July 2022 in both 3.5 mL and 7.5 mL size formats.

LUMIFY® was approved by the U.S. Food and Drug Administration in the United States in 2017. Since then, LUMIFY® has been honored with more than 10 awards, including being named to IRI's 2019 New Product Pacesetters™ 25th annual report and BASES, a Nielsen Global Consumer business division, 2020 U.S. BASES Top 25 Breakthrough Innovations List in the "Superstar" category.

LUMIFY® is licensed by Eye Therapies, Inc. to Bausch + Lomb.

About Bausch + Lomb Bausch + Lomb is dedicated to protecting and enhancing the gift of sight for millions of people around the world – from the moment of birth through every phase of life. Its comprehensive portfolio of more than 400 products includes contact lenses, lens care products, eye care products, ophthalmic pharmaceuticals, over-the-counter products and ophthalmic surgical devices and instruments. Founded in 1853, Bausch + Lomb has a significant global research and development, manufacturing and commercial footprint with more than 12,000 employees and a presence in nearly 100 countries. Bausch + Lomb is headquartered in Vaughan, Ontario with corporate offices in Bridgewater , New Jersey . For more information, visit  www.bausch.com and connect with us on Twitter, LinkedIn, Facebook and Instagram. For more information in Canada , visit. www.bausch.ca.

Forward-looking Statements This news release may contain forward-looking statements, which may generally be identified by the use of the words "anticipates," "hopes," "expects," "intends," "plans," "should," "could," "would," "may," "believes," "estimates," "potential," "target," or "continue" and variations or similar expressions. These statements are based upon the current expectations and beliefs of management and are subject to certain risks and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. These risks and uncertainties include, but are not limited to, the risks and uncertainties discussed in Bausch + Lomb's filings with the U.S. Securities and Exchange Commission and the Canadian Securities Administrators, which factors are incorporated herein by reference. They also include, but are not limited to, risks and uncertainties caused by or relating to the evolving COVID-19 pandemic, and the fear of that pandemic and its potential effects, the severity, duration and future impact of which are highly uncertain and cannot be predicted, and which may have a material adverse impact on Bausch + Lomb, including but not limited to its project development timelines, launches and costs (which may increase). Readers are cautioned not to place undue reliance on any of these forward-looking statements. These forward-looking statements speak only as of the date hereof. Bausch + Lomb undertakes no obligation to update any of these forward-looking statements to reflect events or circumstances after the date of this news release or to reflect actual outcomes, unless required by law. 

LUMIFY® Product Monograph dated July 5, 2021 .

McLaurin E, Cavet ME, Gomes PJ, Ciolino JB. Brimonidine ophthalmic solution 0.025% for reduction of ocular redness: A randomized clinical trial. Optom Vis Sci. 2018;95(3):264-271.

In Home Use Test survey conducted in March, 2018 (n=301).

LUMIFY is a trademark of Bausch & Lomb Incorporated or its affiliates. © 2022 Bausch & Lomb Incorporated or its affiliates. LUM.0087.USA.22

Investor Contacts:                               

Arthur Shannon                                     

arthur.shannon@bauschhealth.com     

Allison Ryan                                             

allison.ryan@bauschhealth.com               

Kristy Marks                      

(877) 354-3705 (toll free)                           

kristy.marks@bausch.com 

(908) 927-0735                                         

View original content to download multimedia:https://www.prnewswire.com/news-releases/bausch--lomb-receives-health-canada-approval-of-lumify-redness-reliever-eye-drops-301553036.html

Bill Gates looks for income, too. This is how he gets it.

‘Rich Dad Poor Dad’ sees a window to get rich. He might be right.

Feeling bearish? Take shelter — and income.

There's a lot of pride associated with owning property, whether it's a primary home or a vacation bungalow. It's especially rewarding when real estate is properly compensated for. But while a high selling price may be exciting in the moment, … Continue reading → The post How to Avoid Capital Gains Tax When Selling a House appeared first on SmartAsset Blog.

Among six high-profile stock splits -- Alphabet, Amazon, Tesla, Shopify, DexCom, and Palo Alto Networks -- is a clear-cut bargain, as well as a company with serious red flags.

The housing market is changing fast. Act accordingly.

Nio (NYSE: NIO) is a leading player in China's electric vehicle (EV) market and has sometimes been referred to as the "Chinese Tesla." Should investors treat Nio's big valuation pullback as an opportunity to build a position in the stock, or is the EV company's share price still too high to generate strong returns? Howard Smith: Nio's recently released quarterly earnings report provided a good lesson for investors wanting to log big returns on more speculative, high-growth companies.

There's a bond that pays a 9.62% interest rate and is guaranteed by the U.S. Treasury. Investors should keep some limitations and conditions in mind before investing, but as inflation has topped 8% since March 2022, this could be an … Continue reading → The post Want 9.62% Yield Guaranteed? Seriously, Try This Asset appeared first on SmartAsset Blog.

Tough times ahead. But you don't need to sell it all.

In this article, we discuss the 10 best energy stocks to buy now. If you want to skip our industry overview, take a look at the 5 Best Energy Stocks to Buy Now. The Covid-19 pandemic was difficult for the energy sector. Global travel restrictions brought on by the Covid-19 outbreak reduced demand for oil […]

Berkshire Hathaway's (NYSE: BRK.A)(NYSE: BRK.B) CEO Warren Buffett is one of the best investors of our lifetime. Buffett stands out, in part, because he doesn't tend to follow the crowd, doesn't fear market crashes, and has a knack for putting his cash to work when everyone else is fearful. Buffett has explained that he looks to buy quality companies with management teams he likes and that he buys with the intention of holding on to these investments for years or even decades.

The Commanders took an "L" before Sunday's game even started.

The biotech sector, like most sections of the market, took a sound beating in the year’s first half. Recently, however, the segment’s performance has improved, and that has helped the NASDAQ Biotechnology Index (NBI) pull ahead of the NASDAQ (Up 13% over the past 3 months vs. the NASDAQ’s 3%). The Oppenheimer biotech team thinks there’s a simple explanation for this: “We believe that much of the recent outperformance has been driven by SMID caps, of which many have risen admirably in the past fe

This past week, average 30-year mortgage rates crossed the 6% mark — though many borrowers can still snag lower lower rates than that — after staying below that for most of July and August, Bankrate data revealed. Greg McBride, chief financial analyst at Bankrate, says the economy will slow faster than inflation so more yo-yo action with rates should be expected in September, but it won’t be huge swings we’re seeing. According to the National Association of Realtors, (NAR), data is showing that mortgage rates have already priced in the upcoming Fed rate hikes.

The Biden administration plans next month to broaden curbs on U.S shipments to China of semiconductors used for artificial intelligence and chipmaking tools, several people familiar with the matter said. The Commerce Department intends to publish new regulations based on restrictions communicated in letters earlier this year to three U.S. companies -- KLA Corp, Lam Research Corp and Applied Materials Inc, the people said, speaking on the condition of anonymity. The letters, which the companies publicly acknowledged, forbade them from exporting chipmaking equipment to Chinese factories that produce advanced semiconductors with sub-14 nanometer processes unless the sellers obtain Commerce Department licenses.

In today's volatile market, there's a lot to be said for seeking out boring businesses at cheap prices.

As different as they seem, both quiet-quitters and FIRERS want the same thing.

SINGAPORE (Reuters) -Oil prices fell on Monday with the global fuel demand outlook overshadowed by COVID-19 restrictions in China and the potential for further interest rate hikes in the United States and Europe. Brent crude futures dropped $1.28, or 1.4%, to $91.56 a barrel by 0330 GMT, after settling 4.1% higher on Friday. Prices were little changed last week as gains from a nominal supply cut by the Organization of the Petroleum Exporting Countries (OPEC) and allies including Russia, a group known as OPEC+, were offset by ongoing lockdowns in China, the world's top crude importer.

Former President Donald Trump has been hinting here and there about who his potential running mate would be for the 2024 presidential run, not confirming or denying anything surrounding that notion. That is, until now. In a recent interview with India’s NDTV, Trump was asked if his eldest daughter Ivanka Trump would be his running […]

Building an excellent stock portfolio is a lot like making a fantastic meal. If I only had three stocks to choose from and $50,000 to invest, the following would be my top three stocks to buy: Amazon (NASDAQ: AMZN), Lululemon (NASDAQ: LULU), and Chevron (NYSE: CVX). The first two are growth plays and Chevron adds value to the portfolio.